Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Cutaneous T-cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (973
)
Diffuse Large B Cell Lymphoma (338
)
Mantle Cell Lymphoma (122
)
T Cell Non-Hodgkin Lymphoma (110
)
Small Lymphocytic Lymphoma (102
)
Follicular Lymphoma (82
)
Peripheral T-cell Lymphoma (65
)
Lymphoplasmacytic Lymphoma (63
)
Marginal Zone Lymphoma (37
)
Burkitt Lymphoma (20
)
Mediastinal B Cell Lymphoma (10
)
Non-Hodgkin’s Lymphoma (973
)
Diffuse Large B Cell Lymphoma (338
)
Mantle Cell Lymphoma (122
)
T Cell Non-Hodgkin Lymphoma (110
)
Small Lymphocytic Lymphoma (102
)
Follicular Lymphoma (82
)
Peripheral T-cell Lymphoma (65
)
Lymphoplasmacytic Lymphoma (63
)
Marginal Zone Lymphoma (37
)
Burkitt Lymphoma (20
)
Mediastinal B Cell Lymphoma (10
)
›
Associations
(17)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
KT-333
Sensitive: B - Late Trials
GlobeNewswire - 1 week (New B)
KT-333
Sensitive
:
B
GlobeNewswire - 1wk
KT-333
Sensitive: B - Late Trials
GlobeNewswire - 1 week
KT-333
Sensitive
:
B
GlobeNewswire - 1 week - (New B)
TNFRSF8 positive
Cutaneous T-cell Lymphoma
TNFRSF8 positive
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
SOHO 2023 - 3 weeks (New C4)
brentuximab vedotin
Sensitive
:
A1
SOHO 2023 - 3wk
brentuximab vedotin
Sensitive: A1 - Approval
SOHO 2023 - 3 weeks
brentuximab vedotin
Sensitive
:
A1
SOHO 2023 - 3 weeks - (New C4)
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
bexarotene oral
Sensitive: A1 - Approval
bexarotene oral
Sensitive
:
A1
bexarotene oral
Sensitive: A1 - Approval
bexarotene oral
Sensitive
:
A1
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
vorinostat
Sensitive: A1 - Approval
vorinostat
Sensitive
:
A1
vorinostat
Sensitive: A1 - Approval
vorinostat
Sensitive
:
A1
IL2RA expression
Cutaneous T-cell Lymphoma
IL2RA expression
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
RP6530
Sensitive: B - Late Trials
RP6530
Sensitive
:
B
RP6530
Sensitive: B - Late Trials
RP6530
Sensitive
:
B
TNFRSF8 expression
Cutaneous T-cell Lymphoma
TNFRSF8 expression
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: B - Late Trials
brentuximab vedotin
Sensitive
:
B
brentuximab vedotin
Sensitive: B - Late Trials
brentuximab vedotin
Sensitive
:
B
PD-L1 underexpression
Cutaneous T-cell Lymphoma
PD-L1 underexpression
Cutaneous T-cell Lymphoma
durvalumab + lenalidomide
Sensitive: C3 – Early Trials
durvalumab + lenalidomide
Sensitive
:
C3
durvalumab + lenalidomide
Sensitive: C3 – Early Trials
durvalumab + lenalidomide
Sensitive
:
C3
RPS6 underexpression
Cutaneous T-cell Lymphoma
RPS6 underexpression
Cutaneous T-cell Lymphoma
ruxolitinib
Sensitive: C3 – Early Trials
ruxolitinib
Sensitive
:
C3
ruxolitinib
Sensitive: C3 – Early Trials
ruxolitinib
Sensitive
:
C3
ICOS underexpression
Cutaneous T-cell Lymphoma
ICOS underexpression
Cutaneous T-cell Lymphoma
durvalumab
Sensitive: C3 – Early Trials
durvalumab
Sensitive
:
C3
durvalumab
Sensitive: C3 – Early Trials
durvalumab
Sensitive
:
C3
PD-1 overexpression
Cutaneous T-cell Lymphoma
PD-1 overexpression
Cutaneous T-cell Lymphoma
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
CD70 expression
Cutaneous T-cell Lymphoma
CD70 expression
Cutaneous T-cell Lymphoma
ARGX-110
Sensitive: C3 – Early Trials
ARGX-110
Sensitive
:
C3
ARGX-110
Sensitive: C3 – Early Trials
ARGX-110
Sensitive
:
C3
IL10-L
Cutaneous T-cell Lymphoma
IL10-L
Cutaneous T-cell Lymphoma
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
TNFA-L
Cutaneous T-cell Lymphoma
TNFA-L
Cutaneous T-cell Lymphoma
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
CCL20-L
Cutaneous T-cell Lymphoma
CCL20-L
Cutaneous T-cell Lymphoma
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
TNFRSF8 expression
Cutaneous T-cell Lymphoma
TNFRSF8 expression
Cutaneous T-cell Lymphoma
TUB-010
Sensitive: D – Preclinical
TUB-010
Sensitive
:
D
TUB-010
Sensitive: D – Preclinical
TUB-010
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login